TED clinical trials at University of California Health

1 research study open to eligible people

Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
open to eligible people ages 18 years and up
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
at UCSD

Last updated: January 22, 2025